See All Slides - tctmd.com

Slides

Presentation THT 2025

Relationship Between Changes in Pulmonary Artery Pressure, Blood Pressure and Weight in Response to Titration of Heart Failure Medications During Ambulatory Monitoring

Presenter: Sandip Zalawadiya

February 11, 2025

Presentation THT 2025

Baroreflex Activation Therapy Improves Cardiopulmonary Exercise Tolerance and Aerobic Capacity in Heart Failure With Reduced Ejection Fraction

Presenter: Dmitry Yaranov

February 11, 2025

Presentation THT 2025

Renal Dysfunction as a Primary Mechanism of Symptoms in (Most) Patients With HFpEF

Presenter: Jeffrey Testani

February 11, 2025

Presentation THT 2025

Silencing TTR With Drugs or CRISPR: Benefits and Risks

Presenter: Ahmad Masri

February 11, 2025

Presentation THT 2025

MRAs Redux: New Evidence in Heart Failure

Presenter: Scott Solomon

February 11, 2025

Presentation THT 2025

Novel Therapies for AL Cardiac Amyloidosis – Bi-Specific Antibodies, BCL Inhibitors and More

Presenter: Giada Bianchi

February 11, 2025

Presentation THT 2025

Drug and Device Therapies to Target the Neurohormonal Cascade

Presenter: Rajeev Mohan

February 11, 2025

Presentation THT 2025

Stabilizers for TTR Amyloidosis: Is One Better Than Another

Presenter: Jan Griffin

February 11, 2025

Presentation THT 2025

Comparative Outcomes of Veno-Arterial ECMO (VA-ECMO) vs. IMPELLA vs. Combining VA-ECMO With IMPELLA (ECPELLA) in Cardiogenic Shock

Presenter: Tahira Qadeer

February 11, 2025

Presentation THT 2025

Effects of Sodium Chloride and Volume Supplementation During the Treatment of Acute Heart Failure: A Prospective, Randomized, Mechanistic Study

Presenter: Jan Biegus

February 11, 2025

Advertisement

Slides

Relationship Between Changes in Pulmonary Artery Pressure, Blood Pressure and Weight in Response to Titration of Heart Failure Medications During Ambulatory Monitoring

Baroreflex Activation Therapy Improves Cardiopulmonary Exercise Tolerance and Aerobic Capacity in Heart Failure With Reduced Ejection Fraction

Renal Dysfunction as a Primary Mechanism of Symptoms in (Most) Patients With HFpEF

Silencing TTR With Drugs or CRISPR: Benefits and Risks

MRAs Redux: New Evidence in Heart Failure

Novel Therapies for AL Cardiac Amyloidosis – Bi-Specific Antibodies, BCL Inhibitors and More

Drug and Device Therapies to Target the Neurohormonal Cascade

Stabilizers for TTR Amyloidosis: Is One Better Than Another

Comparative Outcomes of Veno-Arterial ECMO (VA-ECMO) vs. IMPELLA vs. Combining VA-ECMO With IMPELLA (ECPELLA) in Cardiogenic Shock

Effects of Sodium Chloride and Volume Supplementation During the Treatment of Acute Heart Failure: A Prospective, Randomized, Mechanistic Study

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content